Ambry Genetics宣布推出改进版EHR集成乳腺癌风险评估解决方案，该方案采用了升级的Tyrer-Cuzick评分方法，并将乳腺密度纳入评估体系。
这一创新解决方案通过整合电子健康记录系统，为医疗机构提供了更加精准的乳腺癌风险评估工具。升级后的Tyrer-Cuzick评分方法增加了乳腺密度这一重要参数，使得风险评估结果更加全面和准确。
该解决方案的推出标志着Ambry Genetics在个性化医疗和癌症风险评估领域的又一重要进展，有助于医生为患者制定更加精准的预防和筛查策略。
Ambry Genetics宣布推出改进版EHR集成乳腺癌风险评估解决方案，该方案采用了升级的Tyrer-Cuzick评分方法，并将乳腺密度纳入评估体系。
这一创新解决方案通过整合电子健康记录系统，为医疗机构提供了更加精准的乳腺癌风险评估工具。升级后的Tyrer-Cuzick评分方法增加了乳腺密度这一重要参数，使得风险评估结果更加全面和准确。
该解决方案的推出标志着Ambry Genetics在个性化医疗和癌症风险评估领域的又一重要进展，有助于医生为患者制定更加精准的预防和筛查策略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.